Imugene Limited (AU:IMU) has released an update.
Imugene Limited has reached a significant milestone in its MAST trial, with a bile tract cancer patient maintaining a complete response for over two years. The trial, which uses the innovative CF33-hNIS (VAXINIA) virus, has cleared its first cohort for safety, opening doors for further patient enrollment. With FDA Fast Track and Orphan Drug Designations, along with a US patent extension to 2040, Imugene is poised to advance its promising treatment in the oncology market.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
